NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free KROS Stock Alerts $54.27 -3.33 (-5.78%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$53.59▼$58.4350-Day Range$54.19▼$70.4852-Week Range$27.02▼$73.00Volume379,030 shsAverage Volume304,448 shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/APrice Target$86.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Keros Therapeutics alerts: Email Address Keros Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.5% Upside$86.00 Price TargetShort InterestBearish6.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($5.07) to ($5.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.94 out of 5 starsMedical Sector401st out of 925 stocksPharmaceutical Preparations Industry180th out of 430 stocks 4.5 Analyst's Opinion Consensus RatingKeros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKeros Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Keros Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.35% of the outstanding shares of Keros Therapeutics have been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 1.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KROS. Previous Next 2.7 News and Social Media Coverage News SentimentKeros Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for KROS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.07) to ($5.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Keros Therapeutics Stock (NASDAQ:KROS)Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More KROS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KROS Stock News HeadlinesMay 10, 2024 | finance.yahoo.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS TreatmentMay 12, 2024 | Allegiance Gold (Ad)Does this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial HealthMay 8, 2024 | investorplace.comKROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsMay 7, 2024 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Buy" from BrokeragesMay 5, 2024 | americanbankingnews.comKeros Therapeutics (NASDAQ:KROS) Stock Price Up 7.5%May 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | finance.yahoo.comAre Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?March 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012March 25, 2024 | msn.comDyne Therapeutics appoints John Cox CEOMarch 19, 2024 | markets.businessinsider.comStrong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory EnvironmentMarch 17, 2024 | finance.yahoo.comKROS Apr 2024 30.000 putMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 70.000 putMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 65.000 putMarch 16, 2024 | finance.yahoo.comKROS Apr 2024 75.000 callMarch 14, 2024 | finance.yahoo.comKeros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesMarch 5, 2024 | finance.yahoo.comKeros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceMarch 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic CatalystsMarch 1, 2024 | finanznachrichten.deKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | markets.businessinsider.comBuy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial PositionFebruary 29, 2024 | markets.businessinsider.comOptimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy RatingFebruary 28, 2024 | benzinga.comKeros Therapeutics Stock (NASDAQ:KROS), Earnings Estimates, EPS, and RevenueFebruary 28, 2024 | finance.yahoo.comKeros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023February 28, 2024 | globenewswire.comKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/12/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KROS CUSIPN/A CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Stock Price Target$86.00 High Stock Price Target$105.00 Low Stock Price Target$60.00 Potential Upside/Downside+58.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,990,000.00 Net MarginsN/A Pretax Margin-101,319.21% Return on Equity-50.39% Return on Assets-45.69% Debt Debt-to-Equity RatioN/A Current Ratio14.25 Quick Ratio14.25 Sales & Book Value Annual Sales$150,000.00 Price / Sales13,053.74 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book4.89Miscellaneous Outstanding Shares36,080,000Free Float27,821,000Market Cap$1.96 billion OptionableOptionable Beta1.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 68)President, CEO, Treasurer, & Director Comp: $985.58kMr. Christopher Rovaldi M.Sc. (Age 49)Chief Operating Officer Comp: $708.75kMr. Keith C. Regnante MBA (Age 54)Chief Financial Officer Comp: $603.24kMs. Esther Cho J.D.Senior VP, General Counsel & SecretaryMs. Robin WagnerSenior Vice President of Human ResourcesMr. John Oram M.B.A.Senior Vice President of Program & Portfolio ManagementMore ExecutivesKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTDeciphera PharmaceuticalsNASDAQ:DCPHAmphastar PharmaceuticalsNASDAQ:AMPHArdelyxNASDAQ:ARDXAmneal PharmaceuticalsNASDAQ:AMRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 113,563 shares on 5/10/2024Ownership: 4.286%Russell Investments Group Ltd.Sold 12,205 shares on 5/8/2024Ownership: 0.228%ProShare Advisors LLCBought 1,496 shares on 5/8/2024Ownership: 0.020%Swiss National BankBought 9,000 shares on 5/7/2024Ownership: 0.138%GSA Capital Partners LLPBought 1,736 shares on 5/3/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions KROS Stock Analysis - Frequently Asked Questions Should I buy or sell Keros Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares. View KROS analyst ratings or view top-rated stocks. What is Keros Therapeutics' stock price target for 2024? 7 brokerages have issued 12-month price objectives for Keros Therapeutics' shares. Their KROS share price targets range from $60.00 to $105.00. On average, they predict the company's stock price to reach $86.00 in the next year. This suggests a possible upside of 58.5% from the stock's current price. View analysts price targets for KROS or view top-rated stocks among Wall Street analysts. How have KROS shares performed in 2024? Keros Therapeutics' stock was trading at $39.76 on January 1st, 2024. Since then, KROS shares have increased by 36.5% and is now trading at $54.27. View the best growth stocks for 2024 here. When is Keros Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our KROS earnings forecast. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.12. The firm earned $0.08 million during the quarter. The firm's revenue for the quarter was down 97.3% on a year-over-year basis. During the same quarter last year, the company posted ($1.26) EPS. What ETFs hold Keros Therapeutics' stock? ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and BNY Mellon Innovators ETF (BKIV).Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE). When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Keros Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.29%), WCM Investment Management LLC (0.32%), Russell Investments Group Ltd. (0.23%), Swiss National Bank (0.14%), Mirae Asset Global Investments Co. Ltd. (0.04%) and GSA Capital Partners LLP (0.02%). Insiders that own company stock include Christopher Rovaldi, Jennifer Lachey, Julius Knowles and Keith Regnante. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KROS) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
